Enanta Pharmaceuticals, Inc. - Common Stock (NQ:ENTA)

10.66 +0.29 (+2.84%)

Delayed Quote Updated: 12:12 PM EST, Nov 4, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Enanta Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Enanta Pharmaceuticals to Present Data for Zelicapavir and EDP-323, Two Candidates in Development for the Treatment of Respiratory Syncytial Virus (RSV) at IDWeek™ 2025

October 07, 2025

From Enanta Pharmaceuticals, Inc.

Via Business Wire

Enanta Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

October 02, 2025

From Enanta Pharmaceuticals, Inc.

Via Business Wire

Cal-Maine Foods Posts Downbeat Earnings, Joins Enanta Pharmaceuticals, AAR And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗

October 01, 2025

Via Benzinga

4 Analysts Have This To Say About Enanta Pharma ↗

September 15, 2025

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

October 01, 2025

Via Benzinga

Why Ryvyl Shares Are Trading Higher By 97%; Here Are 20 Stocks Moving Premarket ↗

October 01, 2025

Via Benzinga

Enanta Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock

September 30, 2025

From Enanta Pharmaceuticals, Inc.

Via Business Wire

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

September 30, 2025

Via Benzinga

Wondering what's happening in today's after-hours session? ↗

September 30, 2025

As the regular session of the US market on Tuesday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.

Via Chartmill

Enanta Pharmaceuticals Announces Proposed Public Offering of Common Stock

September 30, 2025

From Enanta Pharmaceuticals, Inc.

Via Business Wire

Let's take a look at the stocks that are in motion in today's session. ↗

September 29, 2025

Intrigued by the market activity one hour before the close of the markets on Monday? Uncover the key winners and losers of today's session in our insightful analysis.

Via Chartmill

Enanta Pharmaceuticals Stock Rises 58% – Here’s An Important Update ↗

September 29, 2025

The company reported that a lower hospitalization rate was observed in patients treated with Zelicapavir compared to those treated with placebo, and the drug demonstrated a robust antiviral effect.

Via Stocktwits

10 Health Care Stocks With Whale Alerts In Today's Session ↗

September 29, 2025

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...

Via Benzinga

Enanta's RSV Pill Shows Promise In Cutting Recovery Time For High-Risk Adults ↗

September 29, 2025

Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) on Monday released topline data from RSVHR Phase 2b study of zelicapavir in outpatient adults with acute respiratory syncytial virus (RSV) infection who are...

Via Benzinga

12 Health Care Stocks Moving In Monday's Intraday Session ↗

September 29, 2025

Gainers cbdMD (AMEX:YCBD) shares rose 116.3% to $1.35 during Monday's regular session. The company's market cap stands at $5.5 million. Zura Bio (NASDAQ: ZURA) stock moved upwards by 42.94% to $3.44....

Via Benzinga

Top stock movements in today's session. ↗

September 29, 2025

Keep an eye on the top gainers and losers in Monday's session, as they reflect the most notable price movements.

Via Chartmill

Enanta Pharmaceuticals Reports Positive Topline Results from its Phase 2b Study of Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV) in High-Risk Adults

September 29, 2025

From Enanta Pharmaceuticals, Inc.

Via Business Wire

Why Merus Shares Are Trading Higher By 38%; Here Are 20 Stocks Moving Premarket ↗

September 29, 2025

Shares of Merus NV (NASDAQ: MRUS) rose sharply in today's pre-market trading. Genmab announced plans to acquire Merus for $8 billion in all-cash deal adding breakthrough therapy Petosemtamab to its...

Via Benzinga

12 Health Care Stocks Moving In Friday's After-Market Session ↗

September 26, 2025

Gainers Enanta Pharma (NASDAQ: ENTA) stock rose 15.6% to $9.13 during Friday's after-market session. The market value of their outstanding shares is at $165.6 million.

Via Benzinga

Curious about the stocks that are showing activity after the closing bell on Friday? ↗

September 26, 2025

As the regular session of the US market on Friday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.

Via Chartmill

Enanta Pharmaceuticals to Present Topline Results from its Phase 2b Study Evaluating Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV) in High-Risk Adults

September 26, 2025

From Enanta Pharmaceuticals, Inc.

Via Business Wire

Enanta Pharmaceuticals Announces the Passing of its Beloved and Respected Longtime Chief Financial and Administrative Officer Paul J. Mellett Jr.

September 03, 2025

From Enanta Pharmaceuticals, Inc.

Via Business Wire

Enanta Pharmaceuticals to Participate in September Investor Conferences

August 21, 2025

From Enanta Pharmaceuticals, Inc.

Via Business Wire

Enanta Pharmaceuticals Files Patent Infringement Suit Against Pfizer in the Unified Patent Court of the European Union

August 20, 2025

From Enanta Pharmaceuticals, Inc.

Via Business Wire

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2025

August 11, 2025

From Enanta Pharmaceuticals, Inc.

Via Business Wire

Enanta Pharmaceuticals to Participate in the H.C. Wainwright & Co. “HCW@Home” Series

August 05, 2025

From Enanta Pharmaceuticals, Inc.

Via Business Wire

Enanta Pharmaceuticals to Participate in Baird’s Biotech Discovery Series

July 15, 2025

From Enanta Pharmaceuticals, Inc.

Via Business Wire

FDA Expands AbbVie's Mavyret Label To Include Pediatric Patients With Hepatitis C Infection ↗

June 11, 2025

FDA approves AbbVie's Mavyret for acute hepatitis C, expanding its use to patients 3 and older with or without cirrhosis after positive trial data.

Via Benzinga

Enanta Pharmaceuticals’ Partner AbbVie Receives U.S. FDA Approval of an Expanded Indication for MAVYRET® (glecaprevir/pibrentasvir) as the First and Only Treatment for People with Acute Hepatitis C Virus

June 11, 2025

From Enanta Pharmaceuticals, Inc.

Via Business Wire

Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

May 27, 2025

From Enanta Pharmaceuticals, Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.